Vasanthi Viswanathan

Vasanthi co-founded Kojin Therapeutics and joined the company in June 2020 to serve as Head of Discovery Biology. Prior to her time at Kojin, Vasanthi trained with Prof. Stuart Schreiber and Prof. Brent Stockwell and made seminal discoveries into the molecular mechanisms and pathophysiological relevance of ferroptotic cell death in cancer and beyond. In addition to her work in basic discovery, Vasanthi co-led a multi-disciplinary academic-industry collaboration at the Broad Institute of MIT and Harvard, aimed at therapeutic modulation of ferroptosis biology.

Vasanthi received an AB in biochemical sciences from Harvard College, completed her PhD in Biology at Columbia University and performed post-doctoral training at the Broad Institute of MIT and Harvard. She has published 12 papers, including in top-tier journals such as Nature and is an inventor on multiple patent applications. In 2018, Vasanthi was awarded a STAT Wunderkind in recognition of her work on ferroptosis.